ALXN Stock UPDATES Alexion Pharmaceuticals (ALXN) 168.90 08/14/2014
Post# of 273254
Posted On: 08/14/2014 8:25:26 PM
Alexion Pharmaceuticals (ALXN) 168.90 $ALXN
Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
Business Wire - Wed Aug 13, 3:57PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.
National Association of Professional Women Announces Donna Ames, Sr. Manager, Clinical Project Lead at Alexion Pharmaceuticals, a 2014 Professional Woman of the Year
PRWeb - Mon Aug 11, 11:03PM CDT
NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a powerfully vibrant networking community with over 600,000 members and more than 300 Local Chapters.
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.68%
Comtex SmarTrend(R) - Mon Aug 11, 4:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.24 to a high of $162.18. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $159.60 on volume of 968,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
Earnings Look Back: Alexion Pharmaceuticals Is Down 5.0% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Aug 11, 12:08PM CDT
Two weeks ago on July 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.07 on sales of $510.5 million. The company actually reported EPS of $1.12 on sales of $512.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Alexion Pharmaceuticals have fallen from $167.48 to $159.11, representing a loss of 5.0% in the past 18 days.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri Aug 08, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Here's How Facebook, Alexion Teach Lessons In Tenacity
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Tenacity is among the more difficult yet more rewarding traits CAN SLIM investors eventually learn to cultivate. Buy-and-hold investors keep a stock as it spirals deep into a correction. They wager on faith that the stock will at some point rise to...
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.
Financial Results, FDA Approvals, Orphan Drug Designations, and Certificates - Research Reports on Idenix, Baxter, Alexion, Alere and Zoetis
PR Newswire - Thu Aug 07, 8:10AM CDT
Today, Analysts Review released its research reports regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Baxter International Inc. (NYSE: BAX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Alere Inc. (NYSE: ALR) and Zoetis Inc. (NYSEQ: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5549-100free.
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 1.52% Yesterday
Comtex SmarTrend(R) - Tue Aug 05, 5:26PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $154.56 to a high of $159.75. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $156.21 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 2:40PM CDT
Alkermes (ALKS) incurred loss in the quarter due to higher expenses.
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
Alexion Pharmaceuticals wins European Commission's ODS for Soliris for treating Myasthenia Gravis
M2 - Fri Aug 01, 7:07AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) revealed on Friday the receipt of the European Commission's orphan drug designation (ODD) for Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Business Wire - Fri Aug 01, 5:30AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris(R) (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.
Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
Business Wire - Wed Aug 13, 3:57PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.
National Association of Professional Women Announces Donna Ames, Sr. Manager, Clinical Project Lead at Alexion Pharmaceuticals, a 2014 Professional Woman of the Year
PRWeb - Mon Aug 11, 11:03PM CDT
NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a powerfully vibrant networking community with over 600,000 members and more than 300 Local Chapters.
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.68%
Comtex SmarTrend(R) - Mon Aug 11, 4:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.24 to a high of $162.18. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $159.60 on volume of 968,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
Earnings Look Back: Alexion Pharmaceuticals Is Down 5.0% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Aug 11, 12:08PM CDT
Two weeks ago on July 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.07 on sales of $510.5 million. The company actually reported EPS of $1.12 on sales of $512.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Alexion Pharmaceuticals have fallen from $167.48 to $159.11, representing a loss of 5.0% in the past 18 days.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri Aug 08, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Here's How Facebook, Alexion Teach Lessons In Tenacity
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Tenacity is among the more difficult yet more rewarding traits CAN SLIM investors eventually learn to cultivate. Buy-and-hold investors keep a stock as it spirals deep into a correction. They wager on faith that the stock will at some point rise to...
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.
Financial Results, FDA Approvals, Orphan Drug Designations, and Certificates - Research Reports on Idenix, Baxter, Alexion, Alere and Zoetis
PR Newswire - Thu Aug 07, 8:10AM CDT
Today, Analysts Review released its research reports regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Baxter International Inc. (NYSE: BAX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Alere Inc. (NYSE: ALR) and Zoetis Inc. (NYSEQ: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5549-100free.
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 1.52% Yesterday
Comtex SmarTrend(R) - Tue Aug 05, 5:26PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $154.56 to a high of $159.75. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $156.21 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 1:00PM CDT
Actavis (ACT) second quarter results were boosted by the inclusion of products from the Warner Chilcott acquisition.
Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 2:40PM CDT
Alkermes (ALKS) incurred loss in the quarter due to higher expenses.
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
Alexion Pharmaceuticals wins European Commission's ODS for Soliris for treating Myasthenia Gravis
M2 - Fri Aug 01, 7:07AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (NasdaqGS:ALXN) revealed on Friday the receipt of the European Commission's orphan drug designation (ODD) for Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Business Wire - Fri Aug 01, 5:30AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris(R) (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.
(0)
(0)Scroll down for more posts ▼